Literature DB >> 8557131

Does serologic evidence of remote Chlamydia trachomatis infection and its heat shock protein (CHSP 60) affect in vitro fertilization-embryo transfer outcome?

P Claman1, M N Amimi, R W Peeling, B Toye, P Jessamine.   

Abstract

OBJECTIVE: To examine IVF-ET outcome in patients with and without serologic evidence of Chlamydia trachomatis infection and chlamydia heat shock protein 60 (CHSP 60) antibodies.
DESIGN: Retrospective case control.
SETTING: University-affiliated IVF-ET program. MAIN OUTCOME MEASURES: A total of 195 IVF-ET patients with tubal factor infertility underwent oocyte pick-up, 166 of these women had ET resulting in a total of 37 pregnancies. Serum antibody testing for evidence of remote C. trachomatis and CHSP 60, as well as pregnancy outcome, were determined for all patients.
RESULTS: There were no differences in pregnancy rates or outcomes between C. trachomatis seropositive versus seronegative groups: 27/118 (23%) C. trachomatis seropositive versus 10/77 (13%) C. trachomatis seronegative patients achieved pregnancy per oocyte pick-up. Pregnancy rates per ET were 27/105 (26%) in C. trachomatis seropositive versus 10/61 (16%) C. trachomatis seronegative patients. In the C. trachomatis positive subgroup, significantly higher pregnancy rates were found in the CHSP 60 antibody positive patients: 24/67 (36%) CHSP 60 positive versus 3/51 (6.0%) CHSP 60 negative patients were pregnant after oocyte pick-up (OR = 8.9, 95% CI = 2.3 to 27.5). Pregnancy rates per ET were 24/57 (42%) in CHSP 60 positive versus 3/48 (7%) CHSP 60 negative patients (OR = 10.9, 95% CI = 2.8 to 33.6). There were no significant differences in any group when examining the following pregnancy outcomes: spontaneous abortion, ectopic pregnancy, preterm and multiple pregnancy rates.
CONCLUSIONS: [1] There are no differences in pregnancy rates or outcomes in patients with and without serologic evidence of previous C. trachomatis infections. [2] In women seropositive for C. trachomatis, significantly higher pregnancy rates are found in women who are CHSP 60 antibody positive versus negative. [3] Pregnancy outcomes do not appear to be different between these groups.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557131     DOI: 10.1016/s0015-0282(16)58042-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

1.  Serum progesterone in predicting pregnancy outcome after assisted reproductive technology.

Authors:  M al-Ramahi; S Perkins; P Claman
Journal:  J Assist Reprod Genet       Date:  1999-03       Impact factor: 3.412

Review 2.  Heat shock protein expression and immunity in chlamydial infections.

Authors:  R W Peeling; D C Mabey
Journal:  Infect Dis Obstet Gynecol       Date:  1999

3.  Effect of previous Chlamydia Trachomatis infection on the outcomes of ivf/icsi treatment: a retrospective study.

Authors:  Dan Zhang; Zengyan Wang; Xingyuan Hu; Chunguang Ma; Yuanlin Ma; Yanwen Xu
Journal:  BMC Pregnancy Childbirth       Date:  2022-04-10       Impact factor: 3.007

Review 4.  Female urogenital chlamydia: Epidemiology, chlamydia on pregnancy, current diagnosis, and treatment.

Authors:  Dian Tjahyadi; Bejo Ropii; Kevin Dominique Tjandraprawira; Ida Parwati; Tono Djuwantono; Wiryawan Permadi; Tinchiu Li
Journal:  Ann Med Surg (Lond)       Date:  2022-03-02

5.  Immune consequences of Chlamydia infections in pregnancy and in vitro fertilization outcome.

Authors:  M Askienazy-Elbhar
Journal:  Infect Dis Obstet Gynecol       Date:  1996

6.  Clinical consequences of immune response to CT upper genital tract infection in women.

Authors:  J Henry-Suchet; M Askienazy-Elbhar; J Orfila
Journal:  Infect Dis Obstet Gynecol       Date:  1996

7.  Impact of genital Chlamydia trachomatis infection on reproductive outcomes among infertile women undergoing tubal flushing: a retrospective cohort at a fertility centre in Uganda.

Authors:  Anthony Kayiira; Daniel Zaake; Michael Webba Lwetabe; Peter Sekweyama
Journal:  Fertil Res Pract       Date:  2019-12-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.